Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients With Disseminated Mycobacterium Avium Complex Infection - Related Studies

Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients With Disseminated Mycobacterium Avium Complex Infection

This study has been completed.

Study NCT00001763. Last updated on March 3, 2008. Information provided by National Institutes of Health Clinical Center (CC)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Acquired Immunodeficiency Syndrome

2	Additional conditions recognized in this trial
		Communicable Diseases
		HIV Infections
		Immunologic Deficiency Syndromes
		Infection
		Mycobacterium avium-intracellulare Infection
		Mycobacterium Infections
		Syndrome

3	More general conditions related to this trial
		Actinomycetales Infections
		Bacterial Infections
		Disease
		Gram-Positive Bacterial Infections
		Immune System Diseases
		Lentivirus Infections
		Mycobacterium Infections, Atypical
		Pathologic Processes
		Retroviridae Infections
		RNA Virus Infections
		Sexually Transmitted Diseases
		Sexually Transmitted Diseases, Viral
		Slow Virus Diseases
		Virus Diseases

4	Interventions listed in this trial
		Interleukin-12

5	More general drug interventions related to this trial
		Adjuvants, Immunologic
		Angiogenesis Inhibitors
		Angiogenesis Modulating Agents
		Antineoplastic Agents
		Growth Inhibitors
		Growth Substances
		Immunologic Factors
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

6	Sponsors listed in this trial
		National Institute of Allergy and Infectious Diseases (NIAID)